title: Renaissance of amantadine in the treatment of Parkinson's disease.
authors.affiliation: Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.
authors.forename: Pierre J
authors.initials: PJ
authors.lastname: Blanchet
authors.forename: Leo Verhagen
authors.initials: LV
authors.lastname: Metman
authors.forename: Thomas N
authors.initials: TN
authors.lastname: Chase
mesh_terms: D000547:Amantadine / Q000008:administration & dosage* / Q000009:adverse effects*; D000818:Animals; D000978:Antiparkinson Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy / Q000517:prevention & control; D018698:Glutamic Acid / Q000378:metabolism; D006801:Humans; D007980:Levodopa / Q000009:adverse effects; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D016194:Receptors, N-Methyl-D-Aspartate / Q000187:drug effects / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D000978:Antiparkinson Agents; D016194:Receptors, N-Methyl-D-Aspartate; D018698:Glutamic Acid; D007980:Levodopa; D000547:Amantadine